World Journal of Pharmaceutical Research SJIF Impact ... · Sweety Sihag* and Neha Wadhwa Department of Chemistry and Biochemistry, CCS Haryana Agricultural University, Hisar (Haryana)
Post on 20-Jun-2020
1 Views
Preview:
Transcript
www.wjpr.net Vol 7, Issue 1, 2018. 1285
Sihag et al. World Journal of Pharmaceutical Research
ROLE OF P53: TUMOR SUPPRESSOR GENE
Sweety Sihag* and Neha Wadhwa
Department of Chemistry and Biochemistry, CCS Haryana Agricultural University, Hisar
(Haryana) - 125004, India.
ABSTRACT
The p53 gene like the Rb gene, is a tumor suppressor gene, i.e., its
activity stops the formation of tumors. If a person inherits only one
functional copy of the p53 gene from their parents, they are
predisposed to cancer and usually develop several independent tumors
in a variety of tissues in early adulthood. This condition is rare and is
known as Li-Fraumeni syndrome. However, mutations in p53 are
found in most tumor types and so contribute to the complex network of
molecular events leading to tumor formation. The p53 gene has been
mapped to chromosome 17. In the cell, p53 protein binds DNA, which
in turn stimulates another gene to produce a protein called p21 that
interacts with a cell division-stimulating protein (cdk2). When p21 is
complexed with cdk2 the cell cannot pass through to the next stage of cell division. Mutant
p53 can no longer bind DNA in an effective way and as a consequence the p21 protein is not
made available to act as the 'stop signal' for cell division. Thus cells divide uncontrollably
and form tumors. Help with unraveling the molecular mechanisms of cancerous growth has
come from the use of mice as models for human cancer, in which powerful 'gene knockout'
techniques can be used. The amount of information that exists on all aspects of p53 normal
function and mutant expression in human cancers is now vast, reflecting its key role in the
pathogenesis of human cancers. It is clear that p53 is just one component of a network of
events that culminate in tumor formation.
KEYWORDS: p 53 protein, stop signal, cell divison, gene Knockout.
World Journal of Pharmaceutical Research SJIF Impact Factor 7.523
Volume 7, Issue 1, 1285-1300. Review Article ISSN 2277– 7105
Article Received on
21 Nov. 2017,
Revised on 11 Dec. 2017,
Accepted on 01 January 2018
DOI: 10.20959/wjpr20181-10270
*Corresponding Author
Sweety Sihag
Department of Chemistry
and Biochemistry, CCS
Haryana Agricultural
University, Hisar (Haryana)
- 125004, India.
www.wjpr.net Vol 7, Issue 1, 2018. 1286
Sihag et al. World Journal of Pharmaceutical Research
INTRODUCTION: WHAT ARE TUMOR SUPPRESSOR GENES?
• Tumor suppressor genes are normal genes that slowdown cell division, repair DNA
mistakes, and tell cells when to die (a process known as apoptosis or programmed cell
death).
• When tumor suppressor genes don’t work properly, cells can grow out of control, which
can lead to cancer. About 30 tumor suppressor genes have been identified, includes p53.[1]
• P53 Gene
• THE p53 GENE is a tumor suppressor gene.
• Its activity stops the formation of tumors.
• If a person inherits only one functional copy of the p53 gene from their parents, they are
predisposed to cancer and usually develop several independent tumors in a variety of
tissues in early adulthood. This condition is rare and is known as Li-Fraumeni syndrome.
However, mutations in p53 are found in most tumor types and so contribute to the
complex network of molecular events leading to tumor formation.[2]
• The p53 gene has been mapped to chromosome 17.
• Its molecular 53 kilodalton protein.
• In the cell, p53 protein binds DNA, which in turn stimulates another gene to produce a
protein called p21 that interacts with a cell division-stimulating protein (cdk2). When p21
is complexed with cdk2 the cell cannot pass through to the next stage of cell division.
www.wjpr.net Vol 7, Issue 1, 2018. 1287
Sihag et al. World Journal of Pharmaceutical Research
Mutant p53 can no longer bind DNA in an effective way, and as a consequence the p21
protein is not made available to act as the 'stop signal' for cell division. Thus cells divide
uncontrollably and form tumors.
Mutations in the p53 gene are found in a greater percentage of tumors than any other gene
mutation. The situation with the p53 gene is complicated by the fact that mutation can result
in The loss of tumor suppressor function.
1. Oncogene activity including a dominant negative effect which overides the influence of
the wild type gene.
In the Li-Fraumeni syndrome, there is a germ-line mutation of the p53 gene resulting in a
high incidence of cancer particularly tumors of the adrenal cortex, breast and brain.[1]
P53 can bind to DNA Stabilized by Zn2+
.
The sequence-specific DNA-binding domain of p53 is localized between amino acid residues
102 and 292.
It is protease-resistant and independently folded domain containing a Zn2+
ion that is required
for its DNA-binding activity.
www.wjpr.net Vol 7, Issue 1, 2018. 1288
Sihag et al. World Journal of Pharmaceutical Research
The discovery of p53
Studies of SV40-transformed cells show that a 55-kDa protein is coprecipitated with the
large-T antigen. This association was shown to be the result of an in vivo association between
the two proteins. It was then postulated that this protein could be encoded by the cellular
genome. (It should be kept in mind that no middle-T was found for SV40 and that the
molecular weight of this protein was similar to that of polyoma middle-T antigen). Linzer and
Levine found that the 54-kDa protein was overexpressed in a wide variety of murine SV40
transformed cells, but also in uninfected embryonic carcinoma cells. A partial peptide map
from this 54-kDa protein was identical among the different cell lines, but was clearly
different from the peptide map of SV40 large-T antigen. It was then postulated that SV40
infection or transformation of mouse cells stimulates the synthesis or stability of a cellular
54-kDa protein.[4]
P53: GATEKEEPER OF GENOME
A gene which encodes a protein that regulates all growth can disable to cause potential
cancerous cells to destroy themselves. The gene is an antioncogen.
• ‘P53 guardian of the genome´.
• Transcription factor.
• Key tetrameric protein in mammalian cell
• Regulates critical cellular function involving the G1and G2cell-cycle checkpoints in
response to DNA damage and apoptosis induced by certain stimuli, such as DNA
damaging agents and hypoxia. Inhibits and prevents tumor growth.[2]
www.wjpr.net Vol 7, Issue 1, 2018. 1289
Sihag et al. World Journal of Pharmaceutical Research
• LOCATION
The tumor suppressor gene p53 is located at chromosomes region17p13 and is one of the
most frequently mutated gene in human cancers.
Post-translational modification of p53
The p53 protein is subject to a variety of post-translational modifications.
Phosphorylation and acetylation of p53 generally results in its stabilization and
accumulation in the nucleus, followed by activation. Several protein kinases can
phosphorylate p53.
Mutant p53 is generally phosphorylated and acetylated at sites that are known to stabilize
wild type p53 and could cause accumulation of dysfunctional p53 functioning as an
oncogene.
Overexpression of MDM2 E3 ubiquitin ligase results in the deactivation of p53 in many
tumors.
Role of Acetylation
• The «latent» (inactive) form, the protein is constitutively unstable and adopts a
conformation in which the extreme C-terminal domains hinder the interactions of the
DNA-binding domain with its target.[4]
www.wjpr.net Vol 7, Issue 1, 2018. 1290
Sihag et al. World Journal of Pharmaceutical Research
• Posttranslational modification, acetylation change in conformations promote
DNA binding activation of p53.
• Several lysines in the C-terminus are covalently modified by acetylation, including lysine
320, 373 and 382.
• Acetylation occurs in response to many forms of DNA-damage.
1. Acetylation may contribute to stabilise p53 by concealing lysines used as target sites for
ubiquitin, therefore inhibiting degradation.
2. Acetylation may induce conformational rearrangements of the C- terminus, increasing
DNA binding capacity.
3. Acetylation may play a role in the regulation of compartmentalization of p53 between
nucleus and cytoplasm.
p53 REULATION
The p53 protein is a transcriptional regulator that has been associated with blocking cell cycle
progression and inducing apoptosis in some systems.
These effects may be mediated by the products of genes whose expression is enhanced by
the p53 protein including the p21WAF1/Cip1
gene and the Bax gene.
The p21WAF1/Cip1
is known to be an inhibitor of cyclin-dependent kinase activity and can
block cell cycle progression.
The Bax protein is a promoter of apoptosis. The p53 gene is activated by DNA damage. It
is thought to be important in normal cells to slow the cell cycle when DNA is damaged to
permit DNA repair before the DNA is replicated.
www.wjpr.net Vol 7, Issue 1, 2018. 1291
Sihag et al. World Journal of Pharmaceutical Research
Failing this it may be preferable for the cell to die rather than perpetuate a damaged
genome. Some of the action of the p53 gene on DNA repair may be mediated by
activation of the Growth Arrest DNA damage gene, GADD45.
The function of the p53 protein can be inhibited by binding to the product of the mdm-2 gene.
This may constitute part of a feedback loop because the mdm-2 gene is activated by the p53
protein. When the mdm-2 gene is overexpressed as in some sarcomas it serves as an
oncogene by supressing the function of the p53 protein.[5]
Regulation of p53 Protein Degradation
• Much of the activation of p53 is achieved through p53 protein stabilization.
• Alongwith ubiquitin-proteasome Mdm2 plays a pivotal role.
• The binding of Mdm2 to p53 promotes the ubiquitination of p53 and its subsequent
degradation by the proteasome.[6]
• Covalent Modifications of p53 DNA damage induces covalent modifications of p53 and
Mdm2, particularly phosphorylation (indicated by (P)). Phosphorylation within the
Mdm2-p53 binding interface can block binding and thereby protect p53 from degradation
P53 and Oncogenic signals[7]
• Deregulated oncoproteins induce the synthesis of ARF, which binds to Mdm2 and prevents
its action.
www.wjpr.net Vol 7, Issue 1, 2018. 1292
Sihag et al. World Journal of Pharmaceutical Research
p53–beta-catenin crossregulatory network
p53–beta-caten Induction of p53 by deregulated beta-catenin is strictly dependent on the
ARF protein, product of another important tumor suppressor.
Deregulated beta-catenin elevates the production of ARF mRNA.
The resultant ARF protein binds Mdm2, blocking its ability to promote the ubiquitination
and degradation of p53.[8]
This block probably relies on multiple mechanisms, including direct inhibition of
Mdm2’s E3 ubiquitin ligase activity, physical sequestration of Mdm2 in the cell nucleolus
away from p53 and interference with a postubiquitination step required for Mdm2-
mediated p53 degradation in the proteasome.
When this happens in response to beta-catenin deregulation, the cell phenotype can be
altered in a p53-dependent manner, resulting in an antiproliferative Effect.
In the absence of a functional p53 pathway, beta-catenin is rendered free to exert its
oncogenic effects on the affected cell.
In human tumors, this is often achieved through mutation or deletion of the p53 gene in
crossregulatory network.
www.wjpr.net Vol 7, Issue 1, 2018. 1293
Sihag et al. World Journal of Pharmaceutical Research
p53–Akt crossregulatory network[9]
Akt is a well-established antiapoptotic protein
Activation of Akt dependent on PI3-kinase (PI3 K)
Akt can engage in direct protein–protein interactions with Mdm2. Furthermore, it can
phosphorylate Mdm2 on at least two residues, serines 166 and 186. This phosphorylation
required for the translocation of Mdm2 from the cytoplasm into the nucleus, where it can
target p53 for inactivation and degradation.
p53 positively regulates the expression of the PTEN tumor-suppressor gene
PTEN, responsible for inactivation and loss in human cancer, encodes a
phosphatidylinositide phosphatase, which counteracts the action of PI3 K.
PTEN serves to prevent the activation of Akt, and facilitate apoptosis
www.wjpr.net Vol 7, Issue 1, 2018. 1294
Sihag et al. World Journal of Pharmaceutical Research
p53 also represses the expression of the catalytic subunit of PI3 K.
PI3 K is activator of Akt
The inhibitory effect of p53 lead to Akt inactivation, which may cooperate with the
induction of PTEN and the degradation of Akt to achieve effective p53-mediated
attenuation of Akt function.
Stress activate te p53
FUNCTIONS OF p53
• 1) Cell growth arrest
• 2) DNA repair
• 3) Apoptosis ±programmed cell death
• p53 protein binds in sequence specific manner to sites (p53-Response elements) in certain
genes (p53-Target Genes) such as WAF-1, BAX, MDM2 etc as a transcription factor.
• Resulting regulatory protein checks the cell cycle and directly initiates DNA-damage
repair or cell destruction (Apoptosis) based on the degree of DNA damage.
www.wjpr.net Vol 7, Issue 1, 2018. 1295
Sihag et al. World Journal of Pharmaceutical Research
CELL CYCLE ARREST
Suppression of cell transformation is mediated by specific binding of p53 tetramers to
DNA at its recognition motifs in the promoter of the wild-type p53-activated fragment
(WAF1) gene (synonyms is p21 gene), which codes for a universal inhibitor (p21, or
CDKI) of the cyclindependent kinases that govern cell cycle progression.
When levels of p21 inhibitor rise, the cyclin/CDK complexes it binds to can no longer
phosphorylate Rb proteins (retinoblastoma tumor suppressor protein family).
Underphosphorylated Rb sequesters the E2F transcription factors required for producing
the DNA synthesis machinery and the cell cycle is thus blocked prior to S-phase.
Regulation of this G1/S boundary is a critical checkpoint in the cell cycle and is
potentially inhibited by p21.[10]
P53 and the cell cycle
www.wjpr.net Vol 7, Issue 1, 2018. 1296
Sihag et al. World Journal of Pharmaceutical Research
P53 arrests the cell cycle primarily by upregulating p21 (Cip1/Waf-1), which inactivates
CDK/cyclin.[5]
P53 can also activate apoptosis.
Block DNA Synthesis
p21 inhibitor may also interfere with DNA synthesis directly by binding to proliferating
cell nuclear antigen(PCNA).
PCNA is an essential factor in DNA replication.
A second gene under transcription control by p53 affecting cell cycle kinetics is GADD45
(growth arrest DNA damage).
which encodes a protein that, like p21, inhibits DNA synthesis by binding to PCNA.
Cell Death
In response to DNA damage, p53 can trigger exit from the cell cycle and chromosomal
disintegration by an active enzymatic process of cell death (apoptosis).
The equilibrium of bax and bc1-2, two principal and opposing protein components of
apoptosis regulation that form neutralizing heterodimer complexes, may be shifted by p53
in favor of cell death.
p53 increases levels of the apoptosis-promoting factor BAX, which has the p53
recognition motif in its promoter and represses levels of the apoptosis- blocking protein
bc1-2.
• The p53-induced activation of target genes may result in the induction of growth arrest
either before DNA replication in the G1 phase of the cell cycle or before mitosis in the
G2 phase.
• The growth arrest enables the repair of damaged DNA.
• By programmed cell death, which is often referred to as apoptosis according to its
morphological appearance, the cells damaged beyond repair are eliminated thus
preventing the fixation of DNA damage as mutations.
• Because these processes ensure genomic integrity or destroy the damaged cell, p53 has
been called the guardian of the genome
P53 and Apoptosis[8]
1. P53 protein starts a pathway that releases cytc from mitochondria
www.wjpr.net Vol 7, Issue 1, 2018. 1297
Sihag et al. World Journal of Pharmaceutical Research
2. This cytc comlexes with protein Apaf-1 and together they activate caspases-9
3. Effector caspases starts a pathway that results in cleavage of cell constituents: DNA etc.
4. Later phagocytosis of these remaining components by macrophages mark the end of
apoptosis
The role of caspase
• During apoptosis, the cell is killed by a class of cystein proteases called caspases. More
than 10 caspases have been identified. Some of them (e.g., caspase 8 and 10) are involved
in the initiation of apoptosis, others (caspase 3, 6 and 7) execute the death order by
destroying essential proteins in the cell. The apoptotic process can be summarized as
follows:
1. Activation of initiating caspases by specific signals
2. Activation of executing caspases by the initiating caspases which can cleave inactive
caspases at specific sites.
3. Degradation of essential cellular proteins by the executing caspases with their protease
activity.
Caspase Activation
Comparison between active and inactive forms of caspases. Newly produced caspases are
inactive. Specifically cleaved caspases will dimerize and become active.
www.wjpr.net Vol 7, Issue 1, 2018. 1298
Sihag et al. World Journal of Pharmaceutical Research
Role Of Apoptosis
In each of these diverse areas implicates immense potential manipulation of apoptosis to treat
disease. Research is already underway to harness apoptosis as a therapeutic tool in modern
medicine.[10]
Possibilities include
Control of malignant disease
Delay of premature senescence in neurodegenerative disease
Regulation of inflammatory disease
Treatment of autoimmune disorders
P53: the guardian of genome
www.wjpr.net Vol 7, Issue 1, 2018. 1299
Sihag et al. World Journal of Pharmaceutical Research
DNA Repair
DNA repair prevents the accumulation of mutations.
Every time a cell prepares to divide into 2 new cells, it must duplicateits DNA.
This process is not perfect, and copying errors sometimes occur.
Fortunately, cells have DNA repair genes, which make proteins that proofread DNA. But
if the genes responsible for the repair are faulty, then the DNA can develop abnormalities
that may lead to cancer.
Thus p53 plays a pivotal role in DNA repair and thus combating cancer.
• P53as a biomarker in alzheimer disease
• Fibroblasts derived from AD patients expressed an altered conformational status of p53
and were less sensitive to p53-dependent apoptosis compared to fibroblasts from non-AD
subjects. Results from research show the potential of p53 as a biomarker in AD
CONCLUSION
p53 guards two gates: a gate to life and a gate to death.
www.wjpr.net Vol 7, Issue 1, 2018. 1300
Sihag et al. World Journal of Pharmaceutical Research
Sensing damage of DNA, p53 can initiate two processes to isolate the damaged cell and
prevent its uncontrolled growth.
P53 having the capacity to modulate various cellular processes including growth arrest,
apoptosis, senescence, differentiation, and DNA repair.
Mutation in p53 responsible for uncontrolled cell division and produces cancer cell.
REFERENCES
1. Boon Wee Keng and D. Aguda Baltazar (2006) Akt versus p53 in a Network of
Oncogenes and Tumor Suppressor Genes Regulating Cell Survival and Death Biophys J.,
91(3): 857–865.
2. Oren Moshe (1999) Regulation of the p53 Tumor Suppressor protein J. Biol. Chem., 274:
36031-36034.
3. The p53 tumor suppressor protein Genes and Disease [Internet] NCBI.
4. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH. (1998)
p14ARF links the tumour suppressors RB and p53. Nature, 395: 124-125.
5. Bell S, Klein C, Muller L, Hansen S, Buchner J. (2002). p53 contains large unstructured
regions in its native state. J Mol Biol, 322: 917-927.
6. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-
Johannes A, Fattaey A, McCormick F. (1996). An adenovirus mutant that replicates
selectively in p53-deficient human tumor cells. Science, 274: 373-376.
7. Blagosklonny, MV. (2002). P53: An ubiquitous target of anticancer drugs. International
Journal of Cancer, 98: 161-166.
8. McCormick F. (2001). Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer, 1:
130-141.
9. Strachan T, Read AP. (1999). Human Molecular Genetics 2. Ch. 18, Cancer Genetics
10. Vogelstein B, Lane D, Levine AJ. (2000). Surfing the p53 network. Nature, 408: 307-310.
top related